Evolent Health
EVH
183 hedge funds and large institutions have $611M invested in Evolent Health in 2019 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 84 increasing their positions, 34 reducing their positions, and 39 closing their positions.
231% more call options, than puts
Call options by funds: $6.01M | Put options by funds: $1.82M
147% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 34
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3.72% less ownership
Funds ownership: 100.86% → 97.14% (-3.7%)
5% less funds holding
Funds holding: 192 → 183 (-9)
15% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 39
39% less capital invested
Capital invested by funds: $1.01B → $611M (-$397M)
Top Buyers
| 1 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$32.7M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$16.7M |
| 3 |
Citigroup
New York
|
+$13.4M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$11.1M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$10M |
Top Sellers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$62.4M |
| 2 |
Bank of New York Mellon
New York
|
-$33.9M |
| 3 |
JP Morgan Chase
New York
|
-$32.1M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$10.6M |
| 5 |
D.E. Shaw & Co
New York
|
-$10.2M |
EVH Hedge Fund Activity: Q2 2019 in Review
183 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q2 2019, worth a combined $611M — down 39% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of EVH and 33 opened new positions — a net loss of 6 holders — while 34 trimmed existing stakes and 84 added.
The largest buyer was Glenmede Trust, adding an estimated $32.7M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $62.4M sold.
- 183 institutional investors held Evolent Health (EVH) as of Q2 2019, down from 192 in Q1 2019.
- Funds reported $611M of Evolent Health stock for Q2 2019, down 39% quarter-over-quarter.
- 33 funds opened new Evolent Health positions in Q2 2019 and 39 closed out, a net change of -6 holders.
- The largest Evolent Health buyer in Q2 2019 was Glenmede Trust, an estimated $32.7M added.
- The largest Evolent Health seller in Q2 2019 was Capital Research Global Investors, an estimated $62.4M sold.
Based on aggregated 13F filings for Q2 2019.